Evidence map›Paper›PMID 35434623›Full record

ArticleRSC medicinal chemistry2022

Design, synthesis and anti-mycobacterial evaluation of imidazo[1,2-

Yogesh Mahadu Khetmalis, Surendar Chitti, Anjani Umarani Wunnava, Banoth Karan Kumar, Muthyala Murali Krishna Kumar, Sankaranarayanan Murugesan, Kondapalli Venkata Gowri Chandra Sekhar

Abstract read
In one paragraph

Article in RSC medicinal chemistry, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Imidazo[1,2‑ACS omega · 2026
    Review
  2. Article
  3. Identification of Small Molecules as Zika Virus Entry Inhibitors.International journal of molecular sciences · 2025
    Article
  4. Article
  5. Review
  6. Article
  7. Recent developments of imidazo[1,2-RSC medicinal chemistry · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yogesh Mahadu KhetmalisDepartment of Chemistry, Birla Institute of Technology and Science, Pilani, Hyderabad Campus Jawahar Nagar Hyderabad 500 078 Telangana India kvgc@hyderabad.bits-pilani.ac.in kvgcs.bits@gmail.com +91 40 66303527.
Surendar ChittiDepartment of Chemistry, Birla Institute of Technology and Science, Pilani, Hyderabad Campus Jawahar Nagar Hyderabad 500 078 Telangana India kvgc@hyderabad.bits-pilani.ac.in kvgcs.bits@gmail.com +91 40 66303527.
Anjani Umarani WunnavaCollege of Pharmaceutical Sciences, Andhra University Visakhapatnam Andhra Pradesh 530 003 India.
Banoth Karan KumarMedicinal Chemistry Research Laboratory, Department of Pharmacy, Birla Institute of Technology and Science Pilani 333031 India.ORCID https://orcid.org/0000-0002-9615-6944
Muthyala Murali Krishna KumarCollege of Pharmaceutical Sciences, Andhra University Visakhapatnam Andhra Pradesh 530 003 India.
Sankaranarayanan MurugesanMedicinal Chemistry Research Laboratory, Department of Pharmacy, Birla Institute of Technology and Science Pilani 333031 India.ORCID https://orcid.org/0000-0002-3680-1577
Kondapalli Venkata Gowri Chandra SekharDepartment of Chemistry, Birla Institute of Technology and Science, Pilani, Hyderabad Campus Jawahar Nagar Hyderabad 500 078 Telangana India kvgc@hyderabad.bits-pilani.ac.in kvgcs.bits@gmail.com +91 40 66303527.ORCID https://orcid.org/0000-0002-2319-8297

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Based on the molecular hybridization strategy, thirty-four imidazo[1,2-

Identifiers

PMID35434623
PMCPMC8942254

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.